AMARIN CORP PLC\UK Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
AMARIN CORP PLC\UK (AMRN) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$1.30 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-27.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2018-02-27
- AMARIN CORP PLC\UK adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2015 was -$1.30M.
- AMARIN CORP PLC\UK adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2014 was -$10.10M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2015-12-31 | -$1.30M 10-K · filed 2018-02-27 |
| 2014-12-31 | -$10.10M 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |